Challenges in diagnosing drug-resistant tuberculosis (DR-TB) contribute to a diagnostic gap. Design-locked Targeted Sequencing (TS) assays have the potential to improve DR-TB diagnosis and management.
Sub-groups 1 (empirically treated participants) and sub-group 2 (participants with microbiologically-confirmed TB) are not mutually exclusive as some participants who were started on empiric TB treatm
PCR and IHC Detection of M. avium subsp. paratuberculosis in uninfected terminal small intestine segments (IPP-C), adjacent infected segments (IPP-M), and mesenteric lymph nodes (LN).